Statements

October 2021

October 28, 2021 10/28/2021 Update on the US Development Program for the Investigational Subcutaneous Formulation of ENTYVIO vedolizumab as a Maintenance Therapy in Adults with Moderate to Severe Ulcerative Colitis

August 2021

August 11, 2021 8/11/2021 Remembering Tadataka “Tachi” Yamada

August 6, 2021 8/6/2021 Revision of Takeda’s Executive Compensation Overview

July 2021

July 8, 2021 7/8/2021 European Patient Survey finds Crohn’s Disease Patients Living with Perianal Fistulas...

March 2021

March 31, 2021 3/31/2021 Takeda Provides Status Update on NATPARA US Recall

March 29, 2021 3/29/2021 Takeda Builds on 30-Year Partnership with the World Federation of Hemophilia with a Five-Year Product Donation to the Humanitarian Aid Program

March 4, 2021 3/4/2021 Takeda Announces Strategic Partnership to Accelerate the Development of Enzyre’s Diagnostic Technology Platform That Aims to Improve the Standard of Care for Patients with Bleeding Disorders

September 2020

September 1, 2020 9/1/2020 Update on the U.S. Development Program for the Investigational Subcutaneous Formulation of ENTYVIO® (vedolizumab) as a Maintenance Therapy in Adults with Moderate to Severe Ulcerative Colitis

June 2020

June 22, 2020 6/22/2020 Update of the Financial Impact of the European Commission’s Decision to Release Takeda from Commitment to Divest Shire’s Pipeline Compound SHP647